Arena Pharmaceuticals VOLATILITY and 3 NASDAQ Top Percentage Losers

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Orbotech Ltd. (NASDAQ:ORBK):  The company’s Korean subsidiary and six employees have been charged by government officials in the Seoul Central District Court of the Republic of Korea for allegedly acquiring and misusing confidential customer information, according to an announcement by the company. The Korean subsidiary and its employees stand indicted and an investigation is underway in which the subsidiary is providing co-operation to the authorities. The company claims the allegations are without basis and plans to mount a vigorous defense in respect of the employees and itself. Denying any criminal intent, Orbotech is confident that the Korean judicial system will give full and fair consideration of the facts and defense.

The shares closed at $8.10, down $1.33, or 14.1%. They have traded in a 52-week range of $8.95 to $13.00.

Investing Insights: Wall Street Brief: Research in Motion’s NIGHTMARE, Nike’s BOMBSHELL, and UK Bank Redress.

A123 Systems, Inc. (NASDAQ:AONE): The shares closed at $1.35, down $0.2, or 12.9%. They have traded in a 52-week range of $0.82 to $5.91.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) received FDA approval for its anti-obesity drug, Lorcaserin, Wednesday. The news is still driving activity in the stock. The shares have traded in a 52-week range of $1.23 to $13.50.

Amedisys Inc (NASDAQ:AMED): The shares closed at $11.89, down $1.19, or 9.1%. They have traded in a 52-week range of $9.12 to $27.76.

Don’t Miss: Here are the TOP Healthcare Sector POPS and DROPS.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business